ANIP ANI Pharmaceuticals Inc

$90.12

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/19/2025

About ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and Canada. The company is headquartered in Baudette, Minnesota.

Website: https://www.anipharmaceuticals.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1023024
Address
210 MAIN STREET WEST, BAUDETTE, MN, US
Valuation
Market Cap
$1.49B
P/E Ratio
nan
PEG Ratio
1.06
Price to Book
3.70
Performance
EPS
$-1.04
Dividend Yield
—
Profit Margin
-3.02%
ROE
-4.18%
Technicals
50D MA
$62.92
200D MA
$59.89
52W High
$70.48
52W Low
$52.50
Fundamentals
Shares Outstanding
22M
Target Price
$81.50
Beta
0.49

ANIP EPS Estimates vs Actual

● Estimated
● Actual

ANIP News & Sentiment

Aug 08, 2025 • Motley Fool NEUTRAL
Cg Oncology ( CGON ) Q2 Loss Widens 93%
Cg Oncology ( NASDAQ:CGON ) , a clinical-stage biotechnology company focused on developing therapies for bladder cancer, reported its second quarter fiscal 2025 earnings on August 8, 2025. The company disclosed a net loss that was more than double that of the same quarter in 2024.
Aug 08, 2025 • Zacks Commentary SOMEWHAT-BULLISH
ANI Pharmaceuticals ( ANIP ) Q2 Earnings and Revenues Surpass Estimates
ANI (ANIP) delivered earnings and revenue surprises of +30.43% and +12.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 08, 2025 • GlobeNewswire NEUTRAL
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting -
Aug 08, 2025 • GlobeNewswire SOMEWHAT-BULLISH
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
BAUDETTE, Minn., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( Nasdaq: ANIP ) ( ANI or the Company ) today announced financial results and business highlights for the second quarter ended June 30, 2025.
Aug 07, 2025 • Zacks Commentary NEUTRAL
Sutro Biopharma, Inc. ( STRO ) Reports Q2 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) delivered earnings and revenue surprises of +64.10% and +293.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 01, 2025 • GlobeNewswire SOMEWHAT-BULLISH
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
PRINCETON, N.J., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( "ANI" or the "Company" ) ( NASDAQ: ANIP ) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open.
Sentiment Snapshot

Average Sentiment Score:

0.401
50 articles with scored sentiment

Overall Sentiment:

Bullish

ANIP Reported Earnings

Feb 26, 2025
Dec 31, 2024 (Pre market)
-0.84 Surprise
  • Reported EPS: $-0.55
  • Estimate: $0.29
  • Whisper: —
  • Surprise %: -287.5%
Nov 08, 2024
Sep 30, 2024 (Pre market)
0.25 Surprise
  • Reported EPS: $1.34
  • Estimate: $1.09
  • Whisper: —
  • Surprise %: 22.9%
Aug 06, 2024
Jun 30, 2024 (Pre market)
0.07 Surprise
  • Reported EPS: $1.02
  • Estimate: $0.95
  • Whisper: —
  • Surprise %: 7.4%
May 10, 2024
Mar 31, 2024 (Pre market)
0.21 Surprise
  • Reported EPS: $1.21
  • Estimate: $1.00
  • Whisper: —
  • Surprise %: 21.0%
Feb 29, 2024
Dec 31, 2023 (Pre market)
0.14 Surprise
  • Reported EPS: $1.00
  • Estimate: $0.86
  • Whisper: —
  • Surprise %: 16.3%
Nov 08, 2023
Sep 30, 2023 (Pre market)
0.43 Surprise
  • Reported EPS: $1.27
  • Estimate: $0.84
  • Whisper: —
  • Surprise %: 51.2%
Aug 09, 2023
Jun 30, 2023 (Pre market)
0.6 Surprise
  • Reported EPS: $1.28
  • Estimate: $0.68
  • Whisper: —
  • Surprise %: 88.2%
May 08, 2023
Mar 31, 2023 (Pre market)
0.82 Surprise
  • Reported EPS: $1.17
  • Estimate: $0.35
  • Whisper: —
  • Surprise %: 234.3%
Mar 09, 2023
Dec 31, 2022 (Pre market)
0.09 Surprise
  • Reported EPS: $0.76
  • Estimate: $0.67
  • Whisper: —
  • Surprise %: 13.4%

Financials